TAP PREVACID LABELING CITES EARLIER ACID CONTROL IN PRILOSEC COMPARISON STUDY; SECOND PROTON PUMP INHIBITOR HAS SIMILAR INDICATIONS TO ASTRA-MERCK's
Executive Summary
Takeda-Abbott Pharmaceutical's Prevacid labeling carries data comparing the new proton pump inhibitor to Astra Merck's PPI Prilosec that shows quicker antisecretory action for Prevacid at the recommended doses for erosive esophagitis therapy.